Duopharma Biotech Berhad has contributed approximately RM300,000 in support of the Program Sekolah Angkat MADANI in 2025. In the initiative, the Company is supporting four schools, namely Sekolah Kebangsaan Bukit Naga and Sekolah Kebangsaan Seksyen 24, both in Shah Alam, Sekolah Kebangsaan Batu Unjur in Klang and Sekolah Menengah Kebangsaan Dato’ Abu Bakar Baginda in Bangi.
Duopharma Biotech Berhad achieved another milestone in Halal pharmaceuticals recently, when it received Halal Certification from the Department of Islamic Development Malaysia (JAKIM) for a biosimilar product used in the treatment of anaemia associated with chronic renal failure in adult haemodialysis and predialysis patients and paediatric patients on haemodialysis.
Duopharma Biotech Berhad has appointed Encik Wan Amir-Jeffery Bin Wan Abdul Majid as Group Chief Executive Officer of Duopharma Biotech Berhad effective 1 October 2025. Prior to this appointment, Encik Wan Amir-Jeffery [52], was Duopharma Biotech’s Chief Executive Officer – Group Operations.
Duopharma Biotech Berhad achieved another milestone in Halal pharmaceuticals recently, when it received Halal Certification from the Department of Islamic Development Malaysia (JAKIM) for a biosimilar product used in the treatment of anaemia associated with chronic renal failure in adult haemodialysis and predialysis patients and paediatric patients on haemodialysis.
Duopharma Biotech Berhad achieved another milestone in Halal pharmaceuticals recently, when it received Halal Certification from the Department of Islamic Development Malaysia (JAKIM) for a biosimilar product used in the treatment of anaemia associated with chronic renal failure in adult haemodialysis and predialysis patients and paediatric patients on haemodialysis.
Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.
Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.
Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.
